1. Anthony, SJ, Johnson, CK, Greig, DJ, et al. Global patterns in coronavirus diversity. Virus Evol. 2017;3(1):vex012.
Google Scholar | Crossref | Medline2. Su, S, Wong, G, Shi, W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490–502.
Google Scholar | Crossref | Medline3. Zhu, N, Zhang, D, Wang, W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N E J Med. 2020;382(8):727–733.
Google Scholar | Crossref | Medline4. Tang, B, Bragazzi, NL, Li, Q, Tang, S, Xiao, Y, Wu, J. An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov). Infect Dis Model. 2020;5:248–255.
Google Scholar | Medline5. Wang, D, Hu, B, Hu, C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061–1069.
Google Scholar | Crossref | Medline6. Waters, E, Doyle, J. Systematic reviews of public health in developing countries are in train. Bmj. 2004;328(7439):585.
Google Scholar | Crossref | Medline7. The, LID . Challenges of coronavirus disease 2019. Lancet Infect Dis. 2020;20(3):261.
Google Scholar | Crossref | Medline8. Burki, T . Outbreak of coronavirus disease 2019. Lancet Infect Dis. 2020;20(3):292–293.
Google Scholar | Crossref | Medline9. Vickers, NJ . Animal communication: when I’m calling you, will you answer too? Curr Biol. 2017;27(14): R713–R5.
Google Scholar | Crossref | Medline10. Liu, C, Zhou, Q, Li, Y, et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Publications; 2020.
Google Scholar | Crossref11. Van Kampen, KR, Shi, Z, Gao, P, et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine. 2005;23(8):1029–1036.
Google Scholar | Crossref | Medline12. Lu, H . Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020. 2020;14(1):69–71.
Google Scholar | Crossref | Medline13. Kumar, V, Jung, YS, Liang, PH. Anti-SARS coronavirus agents: a patent review (2008–present). Expert Opin Ther Pat. 2013;23(10):1337–1348.
Google Scholar | Crossref | Medline14. Richardson, P, Griffin, I, Tucker, C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. The Lancet. 2020;395(10223):e30–e1.
Google Scholar | Crossref | Medline15. Sheahan, TP, Sims, AC, Leist, SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):1–14.
Google Scholar | Crossref | Medline16. Wang, M, Cao, R, Zhang, L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271.
Google Scholar | Crossref | Medline17. Guo, D . Old weapon for new enemy: drug repurposing for treatment of newly emerging viral diseases. Virol Sin. 2020;35(3):253–255.
Google Scholar | Crossref | Medline18. Mifsud, EJ, Hayden, FG, Hurt, AC. Antivirals targeting the polymerase complex of influenza viruses. Antiviral Res. 2019;169:104545.
Google Scholar | Crossref | Medline19. Morse, JS, Lalonde, T, Xu, S, Liu, W. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chembiochem. 2020;21(5):730–738.
Google Scholar | Crossref | Medline20. Warren, TK, Wells, J, Panchal, RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014;508(7496):402–405.
Google Scholar | Crossref | Medline21. Qiu, R, Wei, X, Zhao, M, et al. Outcome reporting from protocols of clinical trials of Coronavirus Disease 2019 (COVID-19): a review. medRxiv. 2020.
Google Scholar22. Wagstaff, KM, Sivakumaran, H, Heaton, SM, Harrich, D, Jans, DA. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012;443(3):851–856.
Google Scholar | Crossref | Medline23. Emmott, E, Munday, D, Bickerton, E, et al. The cellular interactome of the coronavirus infectious bronchitis virus nucleocapsid protein and functional implications for virus biology. J Virol. 2013;87(17):9486–9500.
Google Scholar | Crossref | Medline24. V’kovski, P, Gerber, M, Kelly, J, et al. Determination of host proteins composing the microenvironment of coronavirus replicase complexes by proximity-labeling. Elife. 2019;8:e42037.
Google Scholar | Crossref | Medline25. Siegel, D, Hui, HC, Doerffler, E, et al. Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo [2, 1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. ACS Publications; 2017.
Google Scholar | Crossref26. Mulangu, S, Dodd, LE, Davey, RT, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N E J Med. 2019;381(24):2293–2303.
Google Scholar | Crossref | Medline27. Sheahan, TP, Sims, AC, Graham, RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):eaal3653.
Google Scholar | Crossref28. Furuta, Y, Komeno, T, Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proceed Jpn Acad Ser B. 2017;93(7):449–463.
Google Scholar | Crossref29. Tu, YF, Chien, CS, Yarmishyn, AA, et al. A review of SARS-CoV-2 and the ongoing clinical trials. Int J Mol Sci. 2020;21(7):2657..
Google Scholar | Crossref | Medline30. Caly, L, Druce, JD, Catton, MG, Jans, DA, Wagstaff, KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
Google Scholar | Crossref | Medline31. Omrani, AS, Saad, MM, Baig, K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090–1095.
Google Scholar | Crossref | Medline32. Gross, AE, Bryson, ML. Oral ribavirin for the treatment of noninfluenza respiratory viral infections: a systematic review. Ann Pharmacother. 2015;49(10):1125–1135.
Google Scholar | SAGE Journals | ISI33. Chu, C, Cheng, V, Hung, I, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252–256.
Google Scholar | Crossref | Medline34. Que, T, Wong, V, Yuen, K. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003;9(6):399–406.
Google Scholar | Medline35. Agostini, ML, Andres, EL, Sims, AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018;9(2):e00221–18.
Google Scholar | Crossref | Medline36. Cao, B, Wang, Y, Wen, D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N E J Med. 2020;382(19):1787–1799.
Google Scholar | Crossref | Medline37. Rosa, SGV, Santos, WC. Clinical trials on drug repositioning for COVID-19 treatment. Revista Panamericana de Salud Pública. 2020;44:e40.
Google Scholar | Crossref | Medline38. Lasso, G, Mayer, SV, Winkelmann, ER, et al. A structure-informed atlas of human-virus interactions. Cell. 2019;178(6):1526–1541. e16.
Google Scholar | Crossref | Medline39. Johansen, LM, Brannan, JM, Delos, SE, et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med. 2013;5(190):190ra79–ra79.
Google Scholar | Crossref | Medline40. Dyall, J, Coleman, CM, Hart, BJ, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrobial Agents Chemother. 2014;58(8):4885–4893.
Google Scholar | Crossref | Medline41. Zhao, Y, Ren, J, Harlos, K, et al. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature. 2016;535(7610):169–172.
Google Scholar | Crossref | Medline42. Zhou, Y, Hou, Y, Shen, J, Huang, Y, Martin, W, Cheng, F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020;6(1):1–18.
Google Scholar | Crossref | Medline43. Schwarz, S, Wang, K, Yu, W, Sun, B, Schwarz, W. Emodin inhibits current through SARS-associated coronavirus 3a protein. Antiviral Res. 2011;90(1):64–69.
Google Scholar | Crossref | Medline44. Ho, TY, Wu, SL, Chen, JC, Li, CC, Hsiang, CY. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res. 2007;74(2):92–101.
Google Scholar | Crossref | Medline45. Moskowitz, DW, Johnson, FE. The central role of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr Top Med Chem. 2004;4(13):1431–1452.
Google Scholar | Crossref46. Erlandson, KM, Kitch, D, Wester, CW, et al. The impact of statin and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy on cognitive function in adults with human immunodeficiency virus infection. Clin Infect Dis. 2017;65(12):2042–2049.
Google Scholar | Crossref | Medline47. Wang, XJ, Hu, W, Zhang, TY, Mao, YY, Liu, NN, Wang, SQ. Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na+-dependent taurocholate cotransporting polypeptide activity. Antiviral Res. 2015;120:140–146.
Google Scholar | Crossref | Medline48. Ko, C, Park, WJ, Park, S, Kim, S, Windisch, MP, Ryu, WS. The FDA-approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide. Antivir Ther. 2015;20(8):835–842.
Google Scholar | SAGE Journals49. Yang, X, Yu, Y, Xu, J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481.
Google Scholar | Crossref | Medline50. Fang, L, Karakiulakis, G, Roth, M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21.
Google Scholar | Crossref | Medline51. Wan, Y, Shang, J, Graham, R, Baric, RS, Li, F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7):e00127–20.
Google Scholar | Crossref | Medline52. Ferrario, CM, Jessup, J, Chappell, MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605–2610.